Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Tanespimycin and Bortezomib in Treating Patients With Advanced Solid Tumors or Lymphomas

This study has been terminated.
Information provided by (Responsible Party):
National Cancer Institute (NCI) Identifier:
First received: November 9, 2004
Last updated: February 21, 2014
Last verified: October 2011
No Study Results Posted on for this Study
  Study Status: This study has been terminated.
  Estimated Study Completion Date: No date given
  Primary Completion Date: March 2010 (Final data collection date for primary outcome measure)